CCCC
C4 Therapeutics Inc
NASDAQ: CCCC · HEALTHCARE · BIOTECHNOLOGY
$2.83
+10.55% today
Updated 2026-04-30
Market cap
$281.02M
P/E ratio
—
P/S ratio
7.82x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$1 – $4
Volume
3.0M
C4 Therapeutics Inc (CCCC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-292.10%
Operating margin
-210.10%
ROE
-44.40%
ROA
-18.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $19.36M | $-15.71M | -47.66% | -84.64% | -81.14% |
| 2019 | $21.38M | $-34.10M | 100.00% | -165.81% | -159.48% |
| 2020 | $33.20M | $-66.33M | -136.30% | -182.10% | -199.83% |
| 2021 | $45.78M | $-83.89M | 100.00% | -179.39% | -183.23% |
| 2022 | $31.10M | $-128.18M | 100.00% | -416.56% | -412.19% |
| 2023 | $20.76M | $-132.49M | 62.72% | -669.84% | -638.34% |
| 2024 | $35.58M | $-105.32M | 100.00% | -336.15% | -295.96% |
| 2025 | $35.95M | $-104.99M | 77.81% | -290.68% | -292.08% |